Review anchor
Sodium channel protein type 5 subunit alpha
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
Evidence Snapshot
Sodium channel protein type 5 subunit alpha
CHEMBL1980
SINGLE PROTEIN
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Sodium channel protein type 5 subunit alpha as ChEMBL target CHEMBL1980, mapped to UniProt Q14524. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL1980
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-14
www.ebi.ac.uk
UniProt accession
Q14524
Sodium channel protein type 5 subunit alpha
UniProt accession via ChEMBL component mapping
As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-14
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Sodium channel protein type 5 subunit alpha matters
Sodium channel protein type 5 subunit alpha is reviewed as Sodium channel protein type 5 subunit alpha (UniProt Q14524); Sodium channel protein type 5 subunit alpha shows approved-linked disease relevance led by atrial fibrillation. 5 more disease programs remain visible in the same review block.; 5 linked drugs keep this evidence frame grounded.; the current evidence base includes 41 approved drugs, 3603 compounds, and 541 assays, with lead potency reaching pChEMBL 9.6.
Protein context
Sodium channel protein type 5 subunit alpha
Sodium channel protein type 5 subunit alpha Sequence length is 2016 aa.
Review this target as Sodium channel protein type 5 subunit alpha, mapped to UniProt Q14524. Sequence length is 2016 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt Q14524
Protein
Disease context
atrial fibrillation
Sodium channel protein type 5 subunit alpha shows approved-linked disease relevance led by atrial fibrillation. 5 more disease programs remain visible in the same review block. 5 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include AZD1305, AZD7009, FLECAINIDE ACETATE.
Start review with atrial fibrillation because it currently carries approved-linked support. Linked drugs include AZD1305, AZD7009, FLECAINIDE ACETATE, RANOLAZINE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target record
Approved-linked
5 linked drugs
Activity base
Portfolio and assay base
ChEMBL currently tracks 41 approved drugs, 3603 compounds, and 541 assays for this target. The dominant activity type is IC50. CHEMBL3617050 is the current potency anchor at pChEMBL 9.6.
Use CHEMBL3617050 as the tractability anchor when discussing potency (pChEMBL 9.6).
Activity source · ChEMBL 36 via Core Engine
41 approved
pChEMBL 9.6
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Sodium channel protein type 5 subunit alpha matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q14524, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need to see why atrial fibrillation is currently treated as approved-linked support.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
3603
Total Compounds
541
Total Assays
41
Approved Drugs
IC50: 3366.0, KI: 2.0, EC50: 18.0, KD: 3.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL3617050
|
9.6 | IC50 | — |
|
|
No preferred name
CHEMBL4753470
|
8.7 | EC50 | — |
|
|
No preferred name
CHEMBL4061793
|
8.7 | IC50 | — |
|
|
No preferred name
CHEMBL4444707
|
8.5 | IC50 | — |
|
|
No preferred name
CHEMBL2325014
|
8.0 | IC50 | Clinical |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
TETRACAINE
CHEMBL698
|
2005 |
|
|
MIBEFRADIL
CHEMBL45816
|
1997 |
|
|
TERFENADINE
CHEMBL17157
|
1985 |
|
|
LOPERAMIDE
CHEMBL841
|
1976 |
Source Header